Business description
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Management board & Supervisory board
| CEO |
| Ugur Sahin |
| Management board |
| Jens Holstein, Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting |
| Supervisory board |
| Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider |
Company data
| Name: |
BioNTech SE |
| Address: |
An der Goldgrube 12,DE-55131 Mainz |
| Phone: |
+49-6131-9084-0 |
| Fax: |
+49-6131-9084-390 |
| E-mail: |
info@biontech.de
|
| Internet: |
https://biontech.de/de |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
- |
| IPO date: |
- |
